A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
NCT05721937
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: Are currently or recently pregnant Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will consist of pregnant women exposed to abrocitinib during pregnancy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 0 years and older
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- December 9, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Pfizer · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.